Year-end Sale % OFF 
Abstract
<h3>Results:</h3> The search produced a total of 924 results. After duplicate removal and primary review, 41 articles were selected for full review, and 11 studies that reported the outcome of interest were included in the final meta-analysis. In total, 13871 carriers of <i>BRCA1</i> and <i>BRCA2</i> mutations were identified. The pooled prevalence rates of EC and UPSC in <i>BRCA1/2</i> mutations carriers were 82/13827 (0.59%) and 19/11582 (0.16%), respectively. EC prevalence was 46/7429 (0.62%) in <i>BRCA1</i>, and 17/3546 (0.47%) in <i>BRCA2</i> mutation carriers, with RR of 1.18 (95% CI 0.7-2.0). For UPSC, the prevalence was 15/7429 (0.2%) and 3/3546 (0.08%) among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers, respectively, (RR=1.39, 95% CI 0.5-3.7). <h3>Conclusions:</h3> This meta-analysis suggests a slightly increased risk of EC in <i>BRCA</i> mutation carriers, mainly for <i>BRCA1</i>. The absolute risk is low and needs to be balanced with the potential mild increase in surgical morbidity associated with the addition of a hysterectomy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
